Personalize dosing,
based on the clinical context
SIMDIP-DB© quantitatively predicts unstudied drug-drug interactions using an original model, validated on 1,900 published interactions.
Unstudied interactions
remain a clinical blind spot
The majority of drug combinations have never been the subject of a dedicated clinical study. Current tools are limited to qualitative alerts with no quantitative dose adjustment.
Conventional databases flag interaction risk without providing a quantitative dosing recommendation. Clinicians are left without a tool to adjust the dose.
Generic recommendations do not account for the patient's age, genetic polymorphisms, hepatic function, or renal function.
For thousands of drug combinations, no pharmacokinetic study has been published, particularly in pediatrics, cirrhotic patients, or those with renal impairment.
A quantitative AUC ratio for each interaction, accounting for clinical variability factors, even for combinations never tested in a clinical setting.
A pharmacokinetic model
unique and validated
SIMDIP-DB© is built on an original semi-physiological pharmacokinetic model that quantitatively simulates the impact of each interaction on drug plasma exposure.
Based on organ physiological parameters and drug pharmacokinetic parameters. Predicts interactions not yet studied clinically.
Each AUC ratio is a number, not a risk category. Directly convert the value into an adjusted dose for your patient.
The 7 major cytochromes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) as well as the transporters PgP, BCRP, OATP1B1, and OATP1B3.
Optimal dose = Usual dose / AUCr
The AUC ratio (AUCr) measures the increase or decrease in substrate plasma exposure in the presence of the perpetrator.
The adjusted dose is obtained directly by division, in accordance with the definitions in national SmPCs.
A model proven
against the world literature
Designed for
real clinical situations
Beyond basic interactions, SIMDIP-DB© integrates the variability factors that actually determine plasma exposure in each patient.
| Variability factor | Drug alone | By route of administration | Drug with perpetrator | By dose of perpetrator |
|---|---|---|---|---|
| None | ✔ | ✔ | ✔ | |
| Cirrhosis | ✔ | ✔ | ✔ | ✔ |
| Polymorphism | ✔ | ✔ | ✔ | |
| Renal impairment | ✔ | ✔ | ||
| Age (0–20 years) | ✔ |
How you could benefit
SIMDIP-DB© is designed for professionals who need a quantitative answer, not just an alert.
Hospital Clinical Pharmacists
Optimize dosing for polymedicated patients with multiple comorbidities. SIMDIP-DB© provides the AUCr and adjusted dose for each interaction, including in pediatrics and in cirrhotic patients or those carrying a genetic variant.
Biologists / Therapeutic Drug Monitoring
Interpret plasma drug level results in the context of drug-drug interactions or genetic polymorphisms. Deliver personalized advice tailored to the clinical context.
Healthcare Professionals
Analyze the causality of adverse events through the lens of potential pharmacokinetic interactions and other variability factors, particularly pharmacogenetic ones.
Investigators
For clinical trials involving marketed compounds, precisely define inclusion and exclusion criteria regarding permitted or prohibited co-medications. Avoid overly broad exclusions that reduce patient recruitment.
What you want to know
Technical and practical questions about SIMDIP-DB©.
The AUC ratio (AUCr) is the ratio of the area under the plasma concentration-time curve of a drug in the presence of a perpetrator to that in its absence. It is predicted at steady-state, i.e. when the equilibrium concentrations of the victim drug are reached. An AUCr = 2 means exposure is doubled — a potential toxicity risk. An AUCr = 0.5 means it is halved — a potential loss of efficacy. The optimal dose is obtained directly: Adjusted dose = Usual dose / AUCr.
SIMDIP-DB© uses an original semi-physiological pharmacokinetic model that simulates ADME processes (absorption, distribution, metabolism, elimination) from the characteristic parameters of the molecules and the physiological data of the organs. The characteristic parameters are estimated from clinical pharmacokinetic studies. This model, validated on 1,900 published interactions, can extrapolate to drug combinations not yet tested clinically.
SIMDIP-DB© integrates: route of administration (oral or parenteral), perpetrator dose (3 levels), genetic variants of cytochromes (CYP2D6, CYP2C19, CYP2C9) and transporters (BCRP, OATP1B1), hepatic cirrhosis (Child-Pugh grade A/B/C), age (from full-term newborn to 20 years), and renal impairment (creatinine clearance or GFR).
Conventional databases (Theriaque, Vidal, Micromedex…) provide categorical alerts (contraindication, precautionary use) based on observational data. SIMDIP-DB© produces a numeric AUCr for each substrate × perpetrator × patient context triplet, enabling direct dose adjustment, including for interactions not studied in a clinical setting.
Access to SIMDIP-DB© is provided through institutional or industrial licenses, tailored to your context (hospital, pharmaceutical group, CRO, software publisher). Contact us via the form below to discuss the terms. A demonstration access can be arranged upon request.
Let's talk about
your needs
SIMDIP-DB© is available through institutional or industrial licenses. We tailor access terms to your context: public hospital, pharmaceutical group, CRO, clinical software publisher.
For any questions about the science behind the model, the validation data, or integration possibilities, please don't hesitate to contact us.